Adaptive Biotechnologies Corp
ADPTQ1 2023(ADPT Q4 FY2022)Estimated10% AI
AI Revenue %
10%
AI Fair Value
$100.7M
AI Revenue (Q)
$4.8M
Total Revenue (Q)
$47.8M
Source: SEC EDGAR 10-K Filing
View 10-K on SEC.govAnalysis
FY2022 total revenue ~$177.6M implied (9-month revenue $130.1M + Q4 implied ~$47.5M). Single segment reporting in 2022 10-K confirms revenue disaggregated into MRD and Immune Medicine market opportunities but no dollar breakout in available filing text. Same 10% estimate based on IM ~20% share with 50% AI attribution.
Analyzed by claude-opus-4-6
Quoted Figures
Nine months ended September 30, 2022 revenue $130,110K; full-year implied ~$177.6M
10-K filed 2023-02-27, 10-Q filed 2022-11-08
We present disaggregated revenue from contracts with customers by market opportunity...Immune Medicine and Minimal Residual Disease
10-K FY2022, Segment Information
AI Products Identified (Ring 1)
Immune Medicine TCR-Antigen MapAdaptive Immunosequencing
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test (NGS-based)MRD Pharma testing services
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix